ViiV selects projects for HIV/COVID-19 response fund
ViiV received more than 400 applications from across the world, with eligible submissions coming from Africa, Asia, Europe, South America and the US
Read More
Tag: Emergency Response Fund
- Strong clinical data for Breye lead asset danegaptide
- EHP Awards triumph
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
